Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at HC Wainwright from $9.00 to $3.00. They now have a "buy" rating on the stock.
NeutralReport
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at HC Wainwright from $9.00 to $3.00. They now have a "buy" rating on the stock.
Ovid Therapeutics Inc. (NASDAQ: OVID) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
MediumReport
Ovid Therapeutics Inc. (NASDAQ: OVID) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.50. They now have a "neutral" rating on the stock.
LowReport
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.50. They now have a "neutral" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: